Tag: medical-insurance

2 articles

Industry News

NeuroXess participant uses his brain implant to steer AI from sketch to 3D-printed figurine

NeuroXess (脑虎科技), the Shanghai brain-computer interface developer, disclosed on 30 September 2026 that a man with a C4 spinal cord injury, implanted in April 2026 with its fully implanted, fully wireless Triple-Full system, used it to draw a sketch and enter prompts, from which a large AI model generated design options and one was 3D-printed as a figurine. Using AI smart glasses and NeuroXess's XessOS software, he also adjusted his hospital bed and switched lights and household devices by confirming his intent. NeuroXess describes the work as clinical exploration and released no speed or accuracy figures. The Triple-Full system is in a registration trial led at Huashan Hospital that began on 7 July 2026, with an estimated 32 participants and primary completion estimated for 30 January 2027, and entered the National Medical Products Administration's innovative device review in July.

Oct 2

Market Moves

Neuracle has sold 13 brain implants at a listed RMB 475,000 each since July

Neuracle Technology (Shanghai) (博睿康), maker of China's first approved invasive brain-computer interface, has sold 13 NEO-ONE SCI implant systems and implanted 8 since its first commercial sale in July 2026, with more than 70 more in firm and intended orders. The system is listed at RMB 475,000 per set on procurement platforms in 27 provinces and is not covered by any basic medical insurance catalogue. Neuracle made the figures public on 29 September 2026 in its answers to the Shanghai Stock Exchange's first round of questions on its STAR Market listing application, 110 days after the application was accepted. First-half 2026 revenue was RMB 46.3 million, almost all from its non-invasive business and none from the implant, with a net loss of RMB 65.5 million. No listing committee meeting has been scheduled. None of the best-known Western developers of implanted BCIs, Neuralink, Synchron, Precision Neuroscience, Paradromics and Blackrock Neurotech, is publicly listed.

Oct 1